Dialysis provider DaVita Inc. (NYSE: DVA) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 6% year on year to $3.42 billion. Its non-GAAP profit of $2.87 per share was 23.2% above analysts’ consensus estimates.

Is now the time to buy DVA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvements in quality and cost metrics within the CMS Comprehensive Kidney Care Contracting program. Management also emphasized investments in technology and data infrastructure as foundational to clinical and operational excellence.

Looking ahead, DaVita’s updated guidance centers on higher treatment volume expectations and sustained productivity gains. Management pointed to ongoing investments in digital infrastructure and artificial intelligence as key enablers for future efficiency and improved patient care. Rodriguez stated, “We are well positioned to outperform both clinically and operationally as technology evolves.” However, management also noted that factors such as patient mix and Affordable Care Act (ACA) plan enrollment trends could introduce variability as the year progresses, and the company will monitor these developments closely.

Key Insights from Management’s Remarks

Management highlighted the importance of operational rigor, technology adoption, and value-based care models in driving both clinical and financial results this quarter.

• Integrated Kidney Care momentum: The value-based care segment, IKC, posted strong year-over-year improvements in clinical and economic outcomes, with the highest aggregate savings among participants in the CMS CKCC program. This underscores the growing impact of value-based arrangements in DaVita’s business model.
• Productivity gains in labor: Labor productivity exceeded expectations, contributing to lower patient care costs and helping to offset wage growth. Management credited targeted operational changes and technology-driven scheduling tools for these improvements.
• Technology and AI investments: The company advanced its digital and AI strategy, including deploying proprietary tools like ScheduleHub, which optimizes patient and staff scheduling. These efforts are designed to streamline operations and support clinical teams, with early evidence of reduced administrative burden.
• Patient mix and ACA plans: ACA open enrollment trends were slightly more favorable than anticipated, but management cautioned that more patients are selecting lower-tier plans, which may pressure revenue per treatment later in the year. The company is monitoring the mix impact as enrollment data firms up.
• Market share opportunity from competitor closures: Ongoing clinic closures at Fresenius presented opportunities for patient transfers, with DaVita expecting these to contribute to positive treatment growth for the remainder of the year. Management is working to capture share while acknowledging the competitive dynamics in patient retention and physician relationships.

Drivers of Future Performance

DaVita’s outlook for the year is anchored in expectations of modest treatment volume growth, operational efficiencies, and continued technology-driven productivity gains, while remaining cautious about patient mix and reimbursement trends.

• Treatment volume growth: Management raised its forecast for treatment volume, citing better-than-expected underlying performance and anticipated patient transfers resulting from competitor clinic closures. This is expected to moderately boost normalized treatments per day throughout the year.
• Sustained operational efficiencies: Ongoing investments in digital infrastructure and AI tools are projected to drive further productivity improvements and cost containment, supporting the company’s goal of maintaining operating income growth in the low- to mid-single digit range over time.
• Risks from patient mix and reimbursement: Management remains cautious on the evolving mix of patients, particularly the shift toward lower-tier ACA plans and potential declines in commercial insurance mix. These trends could create headwinds for revenue per treatment, and the impact will be closely monitored as the year unfolds.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) evidence that productivity improvements and digital initiatives are translating into sustained operating margin gains, (2) the scale and timing of patient transfers from competitor clinic closures, and (3) the impact of ACA enrollment mix on revenue per treatment. Additionally, we will watch for updates on DaVita’s AI deployment and broader adoption of value-based care models as potential drivers of future performance.

DaVita currently trades at $187.63, up from $157.04 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.